Prelude Therapeutics Leadership

Kris Vaddi, Ph.D. founded Prelude and served as the chief executive officer and member of the board of directors since 2016. Previously, Kris had a 12-year career at Incyte starting as a founding scientist and an executive director in 2002 and most recently as a group vice president. Kris initiated and championed JAK research programs at Incyte that led to the discovery, development and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant® (Baricitinib) for rheumatoid arthritis. Kris received his Doctorate in Veterinary Medicine from APAU in India and his Ph.D. from University of Florida.

Peggy Scherle, PhD is Chief Scientific Officer at Prelude. Prior to joining Prelude, Peggy was Group Vice President, Discovery Biology and Preclinical Pharmacology at Incyte Corporation and oversaw the target validation and preclinical drug discovery efforts. Peggy was one of the original team of scientists that joined Incyte in 2002 and was involved in the discovery and development of the JAK inhibitors, Jakafi®, for the treatment of myelofibrosis and polycythemia vera, and Olumiant®, for rheumatoid arthritis, as well as the advancement of >10 small molecules into clinical studies for cancer, including both targeted therapy and immunotherapy approaches. Prior to Incyte, Peggy held scientific research positions with DuPont Pharmaceuticals Company and Bristol-Myers Squibb. Peggy received her PhD in immunology from the University of Pennsylvania and completed her postdoctoral training at the NIH.

Brian Piper joined Medgenics as VP, Finance and Investor Relations in April 2014. Prior to joining Medgenics, Mr. Piper served as Senior Director, Strategic Investment Group (SIG), for Shire Pharmaceuticals, LLC from 2010 to 2013, as well as several different finance and business development roles with Shire over the past 13 years. Mr. Piper began his affiliation with Shire in 2002 as Director of Finance for Shire's North American Development group in Rockville, MD. In 2004 he established Shire’s first US Investor Relations group, based out of Philadelphia. After three years running US Investor Relations, Mr. Piper transitioned to an alliance management role and spent two years overseas in Dublin, Ireland helping establish geographic expansion strategies. Prior to joining Shire, Mr. Piper held strategic planning roles for Celera Genomics, was Controller for a start-up Contract Research Organization, and worked as a program planner and financial analyst for Otsuka Pharmaceuticals, Inc. Mr. Piper received a B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.

Kris Vaddi, Ph.D. founded Prelude and served as the chief executive officer and member of the board of directors since 2016. Previously, Kris had a 12-year career at Incyte starting as a founding scientist and an executive director in 2002 and most recently as a group vice president. Kris initiated and championed JAK research programs at Incyte that led to the discovery, development and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant® (Baricitinib) for rheumatoid arthritis. Kris received his Doctorate in Veterinary Medicine from APAU in India and his Ph.D. from University of Florida.

Kris Vaddi, Ph.D. founded Prelude and served as the chief executive officer and member of the board of directors since 2016. Previously, Kris had a 12-year career at Incyte starting as a founding scientist and an executive director in 2002 and most recently as a group vice president. Kris initiated and championed JAK research programs at Incyte that led to the discovery, development and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant® (Baricitinib) for rheumatoid arthritis. Kris received his Doctorate in Veterinary Medicine from APAU in India and his Ph.D. from University of Florida.